Generic Co. Asks Fed. Circ. To Undo Loss In Takeda IP Fight
Lupin Pharmaceuticals Inc. is urging the Federal Circuit to reverse a decision that its abbreviated new drug application for a proposed generic infringes one of three patents covering Takeda's antidepressant drug...To view the full article, register now.
Already a subscriber? Click here to view full article